Accelerate your next cell therapy breakthrough
Cell Therapy R&D Solutions
Benchling’s Cell Therapy R&D solutions are trusted by hundreds of cell therapy innovators to accelerate their R&D. It empowers scientists to discover novel cell therapies with modern tools designed to provide complete, end-to-end traceability of samples, increase throughput and efficiency, and streamline cross-team collaboration. Our modern, digital R&D solution combines all the capabilities expected from the latest in silico design tools, ELN, and LIMS into one intuitive package designed for cell therapy R&D.
The Cell Therapy R&D Accelerators provide best practices that shorten time-to-value for research and process development. The Accelerators contain:
Data model – entity relationship diagram (ERD) which serves as an implementation blueprint
Tenant configuration – pre-defined tenant configuration using templates and dashboards for registering entities, tracking results, increasing inventory utilization, and streamlining workflows
Solution Guide – highlight capabilities and latest product features
Benchling’s services support customers from implementation through ongoing success.
Professional Services – solution-specific domain expertise to jumpstart your optimal implementation
Customer Success – continual solution optimization that takes advantage of new feature releases and ongoing industry learning
How we deliver
Dedicated expertise
Our Customer Experience professionals possess deep scientific expertise, as well as training on information technology best practices. They apply this know-how to support cell therapy customers across a wide range of R&D teams.
Continuous oversight
Leverage Benchling's pre-implementation solutions consulting, professional implementation services, and customer success management expertise to help you get the most out of Benchling.
Focused R&D support
Take advantage of Benchling’s foundational implementation guides, developed by our Customer Experience team to support many cell therapy R&D functions.
Powering breakthroughs for over 1,200 biotechnology companies, from startups to Fortune 500s